Ventricular tachycardia and myocardial infarction during antiarrhythmic therapy: a case report

IF 0.3 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Rational Pharmacotherapy in Cardiology Pub Date : 2023-07-27 DOI:10.20996/1819-6446-2023-2914

A. Gurbanova, K. Pereverzeva, S. Yakushin, I. V. Budanova

{"title":"Ventricular tachycardia and myocardial infarction during antiarrhythmic therapy: a case report","authors":"A. Gurbanova, K. Pereverzeva, S. Yakushin, I. V. Budanova","doi":"10.20996/1819-6446-2023-2914","DOIUrl":null,"url":null,"abstract":"The article analyzes the case of the development of ventricular tachycardia and type 2 myocardial infarction (MI) in an 80-year-old patient with a history of coronary artery disease, MI and chronic heart failure. In 2020, the patient was diagnosed with ventricular extrasystole and started antiarrhythmic therapy with diethylamino propionylethoxycarbonylaminophenothiazine 150 mg per day and sotalol 160 mg per day. In 2022, the patient had an episode of clinical death due to ventricular tachycardia with successful resuscitation. A diagnosis of non-ST-elevation acute coronary syndrome was made, coronary angiography was performed, which did not reveal significant coronary stenosis. Upon further examination, the dynamics of biomarkers of myocardial necrosis confirmed the diagnosis of acute MI. In the analyzed case, the development of ventricular tachycardia and MI is most likely associated with the intake of diethylaminopropionylethoxycarbonylaminophenothiazine in combination with sotalol, prescribed in the presence of contraindications to their use.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"8 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rational Pharmacotherapy in Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20996/1819-6446-2023-2914","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 1

Abstract

The article analyzes the case of the development of ventricular tachycardia and type 2 myocardial infarction (MI) in an 80-year-old patient with a history of coronary artery disease, MI and chronic heart failure. In 2020, the patient was diagnosed with ventricular extrasystole and started antiarrhythmic therapy with diethylamino propionylethoxycarbonylaminophenothiazine 150 mg per day and sotalol 160 mg per day. In 2022, the patient had an episode of clinical death due to ventricular tachycardia with successful resuscitation. A diagnosis of non-ST-elevation acute coronary syndrome was made, coronary angiography was performed, which did not reveal significant coronary stenosis. Upon further examination, the dynamics of biomarkers of myocardial necrosis confirmed the diagnosis of acute MI. In the analyzed case, the development of ventricular tachycardia and MI is most likely associated with the intake of diethylaminopropionylethoxycarbonylaminophenothiazine in combination with sotalol, prescribed in the presence of contraindications to their use.

查看原文本刊更多论文

抗心律失常治疗期间室性心动过速和心肌梗死1例报告

本文分析了一例80岁冠心病、心肌梗死和慢性心力衰竭患者室性心动过速和2型心肌梗死(MI)的发展情况。2020年，患者被诊断为室性早搏，并开始使用二乙胺丙炔乙氧羰基氨基吩噻嗪150 mg /天、索他洛尔160 mg /天的抗心律失常治疗。2022年，患者因室性心动过速发生临床死亡，复苏成功。诊断为非st段抬高急性冠状动脉综合征，行冠状动脉造影，未见明显冠状动脉狭窄。进一步检查后，心肌坏死生物标志物的动态变化证实了急性心肌梗死的诊断。在所分析的病例中，室性心动过速和心肌梗死的发生很可能与二乙基氨基丙酰乙氧羰基氨基吩噻嗪与索他洛尔的联合使用有关，在存在使用禁忌的情况下开具处方。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rational Pharmacotherapy in Cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

1.00

自引率

50.00%

发文量

审稿时长

6 weeks

期刊介绍： The primary goals of the Journal are consolidation of information on scientific and practical achievements in pharmacotherapy and prevention of cardiovascular diseases and continuing education of cardiologists and internists. The scientific concept of the edition suggests the publication of information on current achievements in cardiology, the results of national and international clinical trials. The Journal publishes original articles on the results of clinical trials designed to study the effectiveness and safety of drugs, analysis of clinical practice and its compliance with national and international recommendations, expert s’ opinions on a wide range of cardiology issues, associated conditions and clinical pharmacology. There is a heading “Preventive cardiology and public health” in the Journal to stimulate research interest in this highly demanded area. Memories of the outstanding people in medicine including cardiology, which are of great interest to historians of medicine, are published in "Our Mentors” heading.